瑞康医药(002589) - 2019 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2019 was ¥8,741,682,472.81, representing a 22.62% increase compared to ¥7,129,351,483.19 in the same period last year[9] - Net profit attributable to shareholders decreased by 32.26% to ¥189,871,576.87 from ¥280,290,182.77 year-on-year[9] - Basic and diluted earnings per share both decreased by 32.26% to ¥0.126 from ¥0.186 in the same period last year[9] - Net profit for Q1 2019 was ¥285,598,163.83, a decrease of 22.3% from ¥367,399,391.61 in Q1 2018[42] - Earnings per share for Q1 2019 were ¥0.126, down from ¥0.186 in Q1 2018[43] Cash Flow - The net cash flow from operating activities improved significantly to ¥104,506,396.48, compared to a negative cash flow of ¥2,348,141,537.71 in the previous year[9] - Cash received from other operating activities increased by 130.05% year-on-year, mainly due to cash received from asset securitization asset replacement[19] - Cash paid for purchasing goods and receiving services decreased by 48.58% year-on-year, due to extended payment terms with some suppliers[19] - Operating cash inflow for the current period is CNY 6,184,505,729.92, down 15.6% from CNY 7,325,852,841.47 in the previous period[50] - Operating cash outflow for the current period is CNY 6,079,999,333.44, a decrease of 37.5% compared to CNY 9,673,994,379.18 in the previous period[50] Assets and Liabilities - Total assets increased by 6.07% to ¥36,951,072,627.63 from ¥34,836,043,010.23 at the end of the previous year[9] - Current liabilities rose to CNY 23.25 billion, compared to CNY 21.27 billion in the previous year, reflecting an increase of about 9.26%[33] - The total liabilities increased to CNY 25.33 billion, up from CNY 23.53 billion, reflecting a growth of about 7.65%[33] - The company's total assets increased to ¥23,619,606,664.87 in Q1 2019, compared to ¥21,452,298,090.55 in Q1 2018[39] - Total assets amounted to CNY 34.84 billion, with current assets at CNY 28.66 billion and non-current assets at CNY 6.18 billion[58] Shareholder Information - The total number of shareholders at the end of the reporting period was 39,258, with the top ten shareholders holding significant stakes[13] - Major shareholders include Zhang Renhua with 19.13% and Han Xu with 12.46%, both of whom have pledged a portion of their shares[13] - The total equity attributable to shareholders rose to CNY 8.62 billion, compared to CNY 8.45 billion, showing an increase of about 2.02%[34] - Shareholders' equity totaled CNY 11.31 billion, with equity attributable to the parent company at CNY 8.45 billion[59] Expenses - Total operating costs for Q1 2019 were ¥8,341,100,347.78, up 25.5% from ¥6,645,902,862.79 in the same period last year[40] - Sales expenses for Q1 2019 were ¥582,070,406.86, an increase of 28.1% from ¥454,454,742.04 in Q1 2018[40] - Management expenses rose to ¥347,056,830.21, compared to ¥283,131,464.35 in the previous year, reflecting a 22.6% increase[40] - Financial expenses for Q1 2019 were ¥208,600,928.66, significantly higher than ¥62,299,482.65 in Q1 2018, primarily due to increased interest expenses[40] Other Financial Metrics - The weighted average return on equity decreased to 2.22% from 3.54% year-on-year, reflecting a decline of 1.32%[9] - The company reported non-operating income of ¥2,693,090.40 from government subsidies, while total non-recurring losses amounted to ¥1,077,793.29[10] - The company reported an investment loss of ¥2,279,225.04 in Q1 2019, contrasting with a gain of ¥1,388,157.58 in the same period last year[40] - The company has not conducted an audit for the first quarter report, indicating it is unaudited[63] - The company is implementing new financial accounting standards effective January 1, 2019, which may impact future financial reporting[62]